WALTHAM,
Mass., May 24, 2023 /PRNewswire/ -- Syndax
Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage
biopharmaceutical company developing an innovative pipeline of
cancer therapies, today announced that members of its management
team will participate in two upcoming investor conferences:
- A virtual fireside chat at the TD Cowen 4th Annual Oncology
Innovation Summit at 2:30 p.m. ET on
Wednesday, May 31, 2023.
- A fireside chat at the Goldman Sachs Annual Global Healthcare
Conference at 1:40 p.m. ET/
10:40 a.m. PT on Monday, June 12,
2023 in Dana Point, CA.
A live webcast of the fireside chats can be accessed from the
Investor section of the Company's website at www.syndax.com, where
a replay of the events will also be available for a limited
time.
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals is a clinical stage
biopharmaceutical company developing an innovative pipeline of
cancer therapies. Highlights of the Company's pipeline include
revumenib, a highly selective inhibitor of the menin–KMT2A binding
interaction, and axatilimab, a monoclonal antibody that blocks the
colony stimulating factor 1 (CSF-1) receptor, both currently in
pivotal clinical trials. For more information, please visit
www.syndax.com or follow the Company on
Twitter and LinkedIn.
Syndax Contacts
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
View original
content:https://www.prnewswire.com/news-releases/syndax-announces-participation-at-two-upcoming-investor-conferences-301831439.html
SOURCE Syndax Pharmaceuticals, Inc.